Pentixapharm Holding AG
- BID
2.1
- ASK
2.26
- 1,429 Units442 Units
- 07/21, 21:59:01 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
14.29%
Market Cap
75.53 Mil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.63 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 2.1 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 09:55:46 PM | |
| DAILY VOLUME (UNITS) | 18,000 | |
| DAILY HIGH / LOW | 2.23 | 2.06 |
| PREV. DAY'S PRICE | 2.11 | (07/20) |
| CHANGE DAY BEFORE | -0.01 | -0.47 % |
| 52 WEEK HIGH / LOW | 3.4052 (02/20) | 1.234 (11/11) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | 0.09 | -0.49 | -0.63 | -0.87 | -0.95 |
DIVIDENDS PER SHARE | - | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | - | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | - | 1.48 | 1.05 | - | - |
PRICE - SALES RATIO | - | 619.57 | 394.93 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A40AEG |
| ISIN | DE000A40AEG0 |
| SYMBOL | PTP |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | PENTIXAPHARM HLDG NA O.N. |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 35.80 Mil. |
| MARKET CAPITALISATION | 75.53 Mil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 6.30 % | 2.28 % | 9.27 % | 12.00 % | 14.29 % | - | - | 54.27 % |
| HIGH | 2.23 | 2.27 | 2.69 | 3.41 | 3.41 | - | - | 3.41 |
| LOW | 1.90 | 1.90 | 1.87 | 1.64 | 1.23 | - | - | 1.37 |
Dividende
pro Aktie
PENTIXAPHARM HLDG NA O.N. does not deliver dividend information
Company profile
Pentixapharm Holding AG engages in the development of radiopharmaceutical approaches for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. The company was founded in 2024 and is headquartered in Wuerzburg, Germany.
Structured products for Pentixapharm Holding AG
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
(in 16 days)
08/06/26Q2 2026 Earnings Release
(in 114 days)
11/12/26Q3 2026 Earnings Release
(in 273 days)
04/20/27Q4 2026 Earnings Release
(in 296 days)
05/13/27Q1 2027 Earnings Release
(in 387 days)
08/12/27Q2 2027 Earnings Release